Nedim Katica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nedim Katica has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Mirhan Salibasic
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina
2 shared publications - Nejra Selak
Department of Pathology, Faculty of Medicine, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina
2 shared publications - Sadat Pusina
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina
2 shared publications - Timur Cerić
Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
2 shared publications - Vedad Dedic
Department of General, Abdominal and Glandular Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
2 shared publications - Emir Bicakcic
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 12 (4) , 494-501
Predictive Value of Inflammatory Indexes as Biomarkers of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
Background: Breast cancer remains the most common cancer in women worldwide. Treatment has evolved into multimodal approaches, with pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) serving as a key prognostic marker. The aim of this study was to evaluate the value of inflammatory markers in predicting pCR to NAC in breast cancer. Methods: This cross-sectional study of 74 patients with breast cancer who underwent NAC followed by surgery included demographic, tumor, and immune-inflammatory marker data. Receiver operating characteristic curve analysis and the Youden index were used to determine optimal cutoff values. Univariate and multivariate logistic regression assessed associations between markers and pCR, adjusting for tumor stage, human epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) status. Results: Our multivariate analysis identified the pan-immune-inflammation value (PIV), HER2 status, and ER status as significant independent predictors of pCR. PIV (OR, 4.28; 95% CI, 1.59–16.88) remained significant among inflammatory markers, while the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) did not. HER2-positive (OR, 7.45; 95% CI, 2.30–24.15) and hormone receptor (HR)–negative (OR, 7.02; 95% CI, 2.63–18.70) statuses were also strongly associated with pCR. Conclusion: PIV is a robust predictor of pCR in patients with breast cancer receiving NAC, offering a comprehensive reflection of the immune-inflammatory state. Incorporating PIV with tumor-specific markers (e.g., receptor status, Ki-67, grade) may enhance treatment stratification. Further validation in diverse cohorts is warranted.
- 22 October 2025
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 12 (4) , 494-501
Open AccessPredictive Value of Inflammatory Indexes as Biomarkers of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
Background: Breast cancer remains the most common cancer in women worldwide. Treatment has evolved into multimodal approaches, with pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) serving as a key prognostic marker. The aim of this study was to evaluate the value of inflammatory markers in predicting pCR to NAC in breast cancer. Methods: This cross-sectional study of 74 patients with breast cancer who underwent NAC followed by surgery included demographic, tumor, and immune-inflammatory marker data. Receiver operating characteristic curve analysis and the Youden index were used to determine optimal cutoff values. Univariate and multivariate logistic regression assessed associations between markers and pCR, adjusting for tumor stage, human epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) status. Results: Our multivariate analysis identified the pan-immune-inflammation value (PIV), HER2 status, and ER status as significant independent predictors of pCR. PIV (OR, 4.28; 95% CI, 1.59–16.88) remained significant among inflammatory markers, while the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) did not. HER2-positive (OR, 7.45; 95% CI, 2.30–24.15) and hormone receptor (HR)–negative (OR, 7.02; 95% CI, 2.63–18.70) statuses were also strongly associated with pCR. Conclusion: PIV is a robust predictor of pCR in patients with breast cancer receiving NAC, offering a comprehensive reflection of the immune-inflammatory state. Incorporating PIV with tumor-specific markers (e.g., receptor status, Ki-67, grade) may enhance treatment stratification. Further validation in diverse cohorts is warranted.
- 1 July 2025
- Published by Medical Association of the Sarajevo Canton in Sarajevo Medical Journal
- Vol. 2 (1) , 20-25
Retrospective Analysis of Predictive Factors for Axillary Non-Sentinel Lymph Node Metastases in Sentinel Node-Positive Early-Stage Breast Cancer Patients
Introduction. Sentinel lymph node biopsy (SLNB) has significantly advanced axillary staging in clinically node-negative breast cancer, offering lower morbidity compared to traditional axillary lymph node dissection (ALND). Nonetheless, precise prediction of non-sentinel lymph node (non-SLN) involvement remains essential for optimizing surgical decisions and preventing unnecessary ALND. Methods. A retrospective cohort analysis was performed on 176 patients with clinically node-negative breast cancer who underwent SLNB. Clinicopathological data were reviewed to evaluate associations between various predictive factors and non-SLN involvement. Variables analyzed included tumor size, histological grade, lymphovascular invasion (LVI), Ki-67 proliferation index, and sentinel lymph node characteristics. Results. Multivariable logistic regression identified the type of SLN metastasis (OR=21.4; 95% CI 1.7–43.6; p=0.01), the number of positive SLNs (OR=5.66; 95% CI 1.18–36.6; p=0.03), and the number of negative SLNs (OR=0.04; 95% CI 0.006–0.27; p=0.001) as independent predictors of non-SLN metastases. The predictive model demonstrated excellent discriminatory power, with an area under the receiver operating characteristic curve (AUC) of 0.91. Conclusion. Specific clinical and histopathological variables reliably predict non-SLN involvement in SLN-positive breast cancer patients. Incorporation of these predictors into clinical practice may enhance individualized axillary management and reduce unnecessary ALND procedures. Further validation through larger prospective studies is warranted. Key words: Breast Neoplasms, Sentinel Lymph Node Biopsy, Axillary Lymph Nodes, Lymph Node Dissection, Neoplasm Staging.
- 1 July 2025
- Published by Medical Association of the Sarajevo Canton in Sarajevo Medical Journal
- Vol. 2 (1) , 20-25
Retrospective Analysis of Predictive Factors for Axillary Non-Sentinel Lymph Node Metastases in Sentinel Node-Positive Early-Stage Breast Cancer Patients
Introduction. Sentinel lymph node biopsy (SLNB) has significantly advanced axillary staging in clinically node-negative breast cancer, offering lower morbidity compared to traditional axillary lymph node dissection (ALND). Nonetheless, precise prediction of non-sentinel lymph node (non-SLN) involvement remains essential for optimizing surgical decisions and preventing unnecessary ALND. Methods. A retrospective cohort analysis was performed on 176 patients with clinically node-negative breast cancer who underwent SLNB. Clinicopathological data were reviewed to evaluate associations between various predictive factors and non-SLN involvement. Variables analyzed included tumor size, histological grade, lymphovascular invasion (LVI), Ki-67 proliferation index, and sentinel lymph node characteristics. Results. Multivariable logistic regression identified the type of SLN metastasis (OR=21.4; 95% CI 1.7–43.6; p=0.01), the number of positive SLNs (OR=5.66; 95% CI 1.18–36.6; p=0.03), and the number of negative SLNs (OR=0.04; 95% CI 0.006–0.27; p=0.001) as independent predictors of non-SLN metastases. The predictive model demonstrated excellent discriminatory power, with an area under the receiver operating characteristic curve (AUC) of 0.91. Conclusion. Specific clinical and histopathological variables reliably predict non-SLN involvement in SLN-positive breast cancer patients. Incorporation of these predictors into clinical practice may enhance individualized axillary management and reduce unnecessary ALND procedures. Further validation through larger prospective studies is warranted. Key words: Breast Neoplasms, Sentinel Lymph Node Biopsy, Axillary Lymph Nodes, Lymph Node Dissection, Neoplasm Staging.